Výsledky vyhledávání - "Christina L Gersch"

Akademický článek

PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.

Autor: Elizabeth P Darga, Emily M Dolce, Fang Fang, Kelley M Kidwell, Christina L Gersch, Steven Kregel, Dafydd G Thomas, Anoop Gill, Martha E Brown, Steven Gross, Mark Connelly, Michael Holinstat, Erin F Cobain, James M Rae, Daniel F Hayes, Costanza Paoletti

Publikováno v: PLoS ONE, Vol 16, Iss 11, p e0260124 (2021)

BackgroundImmune checkpoint inhibition is effective in several cancers. Expression of programmed death-ligand 1 (PD-L1) on circulating tumor or immune effector cells could provide insights into selection of patients for immune checkpoint inhibition.M

Externí odkaz: https://doaj.org/article/28fe13df1c2442cbb060d80eb7cf2b44

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

Autor: Daniel L. Hertz, Karen Lisa Smith, Yuhua Zong, Christina L. Gersch, Andrea M. Pesch, Jennifer Lehman, Amanda L. Blackford, N. Lynn Henry, Kelley M. Kidwell, James M. Rae, Vered Stearns

Publikováno v: Frontiers in Genetics, Vol 12 (2021)

BackgroundAromatase inhibitors (AI) reduce recurrence and death in patients with early-stage hormone receptor-positive (HR +) breast cancer. Treatment-related toxicities, including AI-induced musculoskeletal symptoms (AIMSS), are common and may lead

Externí odkaz: https://doaj.org/article/b61d8741017e420ebda5a93e03cf4250

Zobrazit plný text záznamu

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

Autor: Daniel L Hertz, Julie A Douglas, Robert M Miller, Kelley M Kidwell, Christina L Gersch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd C Skaar, Daniel F Hayes, N. Lynn Henry, James M Rae

Publikováno v: Support Care Cancer

Objective Aromatase inhibitors (AI) are commonly used to treat hormone receptor positive (HR+) breast cancer. AI-induced musculoskeletal syndrome (AIMSS) is a common toxicity that causes AI treatment discontinuation. The objective of this genome-wide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b35c2fbbf6eb6a47e81445b841e30ef
https://doi.org/10.1007/s00520-022-07243-8

Zobrazit plný text záznamu

Data from Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers

Autor: Corey W. Speers, James M. Rae, Lori J. Pierce, José M. Larios, Christina L. Gersch, Meilan Liu, Kari Wilder-Romans, Marlie P. Androsiglio, Cassandra L. Ritter, Anna R. Michmerhuizen, Benjamin C. Chandler, Nicole H. Hirsh, Andrea M. Pesch

Purpose:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved progression-free survival for metastatic, estrogen receptor–positive (ER+) breast cancers, but their role in the nonmetastatic setting remains unclear. We sought to understand th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352f4e1af5ba38fbb7d886201cb5ba6b
https://doi.org/10.1158/1078-0432.c.6529395.v1

Zobrazit plný text záznamu

Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity

Autor: Julie A. Douglas, Daniel L. Hertz, N. Lynn Henry, Zeruesenay Desta, Daniel F. Hayes, Todd C. Skaar, James M. Rae, Christina L. Gersch, Vered Stearns, Ana Maria Storniolo, Kelley M. Kidwell

Publikováno v: Pharmacogenet Genomics

OBJECTIVE: Letrozole is a non-steroidal aromatase inhibitor (AI) used to treat hormone receptor positive (HR+) breast cancer. Variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure, which may b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c81e74856e2751dcbc047f621021d3
https://doi.org/10.1097/fpc.0000000000000429

Zobrazit plný text záznamu

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus

Autor: James M. Rae, Jeong M. Park, Michael Englesbe, Christina L. Gersch, Amy L. Pasternak, Vincent D. Marshall

Publikováno v: Pharmacogenomics and Personalized Medicine

Amy L Pasternak,1 Vincent D Marshall,1 Christina L Gersch,2 James M Rae,2 Michael Englesbe,3 Jeong M Park1 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, 48109, USA; 2Department of Internal Medicine, Mich

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0ca7c8a8037bf5678202912dce34ad
https://doi.org/10.2147/pgpm.s285444

Zobrazit plný text záznamu

Abstract PS5-25: Association of OPG rs2073618 and aromatase inhibitor induced musculoskeletal symptoms

Autor: Karen L. Smith, Christina L. Gersch, Kelley M. Kidwell, Daniel L. Hertz, Arti Patel, James M. Rae, Yuhua Zong, N. Lynn Henry, Vered Stearns, Jennifer Lehman, Andrea M. Pesch

Publikováno v: Cancer Research. 81:PS5-25

Background: Adjuvant aromatase inhibitors (AI) reduce recurrence and mortality after early stage hormone receptor-positive (HR+) breast cancer (BC). Treatment-related toxicities, including AI-induced musculoskeletal symptoms (AIMSS), are common durin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65eeeb6a3b7238253cccb589ecdc6adf
https://doi.org/10.1158/1538-7445.sabcs20-ps5-25

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání